GS
ABCL icon

GTS Securities’s AbCellera Biologics ABCL Stock Holding History

GTS Securities’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-21,479
Closed -$55.8K – 1234
2024
Q3 		$55.8K Buy
21,479
+3,124
+17% +$8.66K ﹤0.01% 3879
2024
Q2 		$54.3K Sell
18,355
-9,085
-33% -$34.4K ﹤0.01% 3699
2024
Q1 		$124K Sell
27,440
-4,308
-14% -$22K ﹤0.01% 3478
2023
Q4 		$181K Buy
31,748
+15,605
+97% +$72.3K ﹤0.01% 3605
2023
Q3 		$74.3K Buy
+16,143
New +$98.2K ﹤0.01% 3650

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return